What Nurix Therapeutics Stock's Profit Turnaround Means For Shareholders

Nurix Therapeutics reported third quarter 2026 revenue of US$673.06 million and net income of US$549.81 million, with both basic and diluted earnings per share from continuing operations turning positive compared with losses a year earlier. The nine month results to August 31, 2026 show revenue of US$688.36 million and net income of US$373.1 million, indicating that profitability now reflects a longer stretch of the year rather than a single quarter spike. We will examine how Nurix...